ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Singapore's Temasek expands investment in biotech companies

Sovereign fund leads UK Glympse Bio's $46.7m fundraising

Singapore state-owned investment company Temasek has targeted multiple biotechnology companies for investments.   © Reuters

SINGAPORE -- UK-headquartered Glympse Bio has raised $46.7 million in an oversubscribed series B funding round from a slew of investors, including Singapore state-owned investment company Temasek.

The investment from Temasek marks a continuation of the fund's interest in biotechnology investments.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more